BION Other Assets from 2010 to 2026

BION Stock  CHF 47.05  0.70  1.51%   
BB Biotech Other Assets yearly trend continues to be fairly stable with very little volatility. Other Assets are likely to outpace its year average in 2026. During the period from 2010 to 2026, BB Biotech Other Assets regression line of quarterly data had mean square error of 1483535.9 T and geometric mean of  6,055,212. View All Fundamentals
 
Other Assets  
First Reported
2009-12-31
Previous Quarter
1.9 B
Current Value
1.8 B
Quarterly Volatility
1.1 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check BB Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BB Biotech's main balance sheet or income statement drivers, such as Interest Expense of 6 M, Selling General Administrative of 25.7 M or Total Revenue of 169.9 M, as well as many indicators such as Price To Sales Ratio of 14.91, Dividend Yield of 0.0337 or PTB Ratio of 0.75. BION financial statements analysis is a perfect complement when working with BB Biotech Valuation or Volatility modules.
  
This module can also supplement various BB Biotech Technical models . Check out the analysis of BB Biotech Correlation against competitors.
The evolution of Other Assets for BB Biotech AG provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how BB Biotech compares to historical norms and industry peers.

Latest BB Biotech's Other Assets Growth Pattern

Below is the plot of the Other Assets of BB Biotech AG over the last few years. It is BB Biotech's Other Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BB Biotech's overall financial position and show how it may be relating to other accounts over time.
Other Assets10 Years Trend
Slightly volatile
   Other Assets   
       Timeline  

BION Other Assets Regression Statistics

Arithmetic Mean(187,125,004)
Geometric Mean6,055,212
Coefficient Of Variation(870.75)
Mean Deviation1,075,864,830
Median1,000.00
Standard Deviation1,629,392,528
Sample Variance2654920T
Range6.3B
R-Value(0.69)
Mean Square Error1483535.9T
R-Squared0.48
Significance0
Slope(222,649,387)
Total Sum of Squares42478720.2T

BION Other Assets History

2026-2.3 B
2025-2.4 B
2023-2.6 B
202292 K
2021135 K
2020139 K
2019190 K

About BB Biotech Financial Statements

BB Biotech investors use historical fundamental indicators, such as BB Biotech's Other Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BB Biotech. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Assets-2.4 B-2.3 B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for BION Stock Analysis

When running BB Biotech's price analysis, check to measure BB Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BB Biotech is operating at the current time. Most of BB Biotech's value examination focuses on studying past and present price action to predict the probability of BB Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BB Biotech's price. Additionally, you may evaluate how the addition of BB Biotech to your portfolios can decrease your overall portfolio volatility.